Departments of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, USA.
J Pharm Pharmacol. 2012 Sep;64(9):1254-63. doi: 10.1111/j.2042-7158.2012.01476.x. Epub 2012 Feb 21.
The objective of this study was to investigate the in-vitro particle-size growth of combination drug and excipient submicrometer aerosols generated from a series of formulations and two aerosol delivery devices.
Submicrometer combination drug and excipient particles were generated experimentally using both the capillary aerosol generator and the Respimat inhaler. Budesonide and albuterol sulfate were used as model drugs and were formulated with sodium chloride, citric acid and mannitol as excipients in various ratios. Aerosol growth was evaluated in-vitro in a coiled-tube geometry designed to provide residence times and thermodynamic conditions consistent with the airways.
Submicrometer combination drug : excipient aerosols when exposed to simulated respiratory conditions increased to micrometer size suitable for pulmonary deposition. It was possible to control the aerosol growth ratio by altering: (1) the hygroscopic excipient, (2) the drug : excipient ratio and (3) the drug. The applicability of this approach was demonstrated using the capillary aerosol generator and the Respimat inhaler.
The enhanced excipient growth approach may enable the delivery of submicrometer aerosol particles that increase in size within the airways and result in high percentages of pulmonary deposition.
本研究旨在考察一系列配方和两种雾化器产生的联合药物和赋形剂亚微米气溶胶的体外颗粒生长情况。
使用毛细气溶胶发生器和 Respimat 吸入器,对亚微米联合药物和赋形剂颗粒进行了实验生成。布地奈德和硫酸沙丁胺醇被用作模型药物,并与氯化钠、柠檬酸和甘露醇以不同比例作为赋形剂进行了配制。气溶胶的生长在设计用于提供与气道一致的停留时间和热力学条件的螺旋管几何形状中进行了体外评估。
在模拟呼吸条件下,亚微米联合药物:赋形剂气溶胶增加到适合肺部沉积的微米大小。通过改变:(1)吸湿赋形剂,(2)药物:赋形剂比和(3)药物,可以控制气溶胶生长比。该方法的适用性使用毛细气溶胶发生器和 Respimat 吸入器进行了证明。
增强的赋形剂生长方法可以实现亚微米气溶胶颗粒的输送,这些颗粒在气道内增大,导致高比例的肺部沉积。